NCT06282991 2026-03-10A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be ControlledPfizerCompleted73 enrolled 12 charts
NCT06678555 2026-02-05A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.PfizerActive not recruiting35 enrolled
NCT03052608 2025-11-25A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCPfizerPhase 3 Active not recruiting296 enrolled 28 charts 1 FDA
NCT03909971 2025-11-05A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaPfizerPhase 2 Completed109 enrolled 33 charts
NCT04800822 2024-10-22PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT01970865 2024-08-12A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsPfizerPhase 1/2 Completed364 enrolled 89 charts 1 FDA
NCT03546894 2024-07-15A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsTakedaCompleted111 enrolled